OPKO Presents 4Kscore™ Test Clinical Study at the American Urological Association Plenary Session

May 19, 2014 7:04 PM

16 0

MIAMI, May 19, 2014 (BUSINESS WIRE) -- OPKO Health, Inc. /quotes/zigman/465359/delayed/quotes/nls/opk OPK +2.20% announced the results of the data from its blinded, prospective clinical study of the 4Kscore Test at 26 leading Urology centers across the United States. The results demonstrated the 4Kscore Test is the most accurate, personalized predictor for risk of high-grade cancer. The data were presented by Dr. Daniel W. Lin, Professor and Chief of Urologic Oncology at the University of Washington, as a Late-Breaking abstract at the Plenary I Session on Sunday May 18, 2014 at the American Urological Association (AUA) annual meeting in Orlando, FL.

The 4Kscore Test, launched by OPKO on March 31, 2014, provides a patient with his personal risk for high-grade prostate cancer from a blood test. The measurements used in the 4Kscore Test are four kallikrein protein levels from the blood test (Total PSA, Free PSA, Intact PSA and hK2), along with the...

Read more

To category page